Vicapsys Life Sciences (VICP) 10-Q 12 Nov 21 2021 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2021	Nov. 11, 2021
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2021
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2021
Current Fiscal Year End Date	--12-31
Entity File Number	000-56145
Entity Registrant Name	VICAPSYS LIFE SCIENCES, INC.
Entity Central Index Key	0001468639
Entity Tax Identification Number	91-1930691
Entity Incorporation, State or Country Code	FL
Entity Address, Address Line One	7778 Mcginnis Ferry Rd. #270
Entity Address, City or Town	Suwanee
Entity Address, State or Province	GA
Entity Address, Postal Zip Code	30024
City Area Code	(972)
Local Phone Number	891-8033
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		30,114,564

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Current Assets:
Cash	$ 165,549	$ 1,269
Total Current Assets	165,549	1,269
Prepaid expenses	7,240
Intangible asset, net of accumulated amortization of $113,132 and $89,665, respectively	379,383	402,849
Total Assets	552,172	404,118
Current Liabilities:
Accounts payable	496,555	501,732
Accounts payable, related parties	134,180	236,180
Accrued salaries, related parties	115,312	115,312
Total Current Liabilities	746,047	853,224
Stockholders’ Equity (Deficit):
Common Stock, par value $0.001; 300,000,000 shares authorized; 17,507,283 and 17,483,283 shares issued and outstanding, respectively	17,507	17,483
Common stock to be issued, par value $0.001; 12,607,281 and 651,281 shares outstanding, respectively	12,607	651
Additional paid-in capital	13,801,778	13,418,074
Accumulated deficit	(14,025,767)	(13,892,754)
Total Stockholders’ Deficit	(193,875)	(449,106)
Total Liabilities and Stockholders’ Deficit	552,172	404,118
Series A Preferred Stock [Member]
Stockholders’ Equity (Deficit):
Preferred stock value		3,000
Series B Preferred Stock [Member]
Stockholders’ Equity (Deficit):
Preferred stock value		$ 4,440

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Intangible asset, net of accumulated amortization	$ 113,132	$ 89,665
Preferred stock par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	20,000,000	20,000,000
Common stock par value	$ 0.001	$ 0.001
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	17,507,283	17,483,283
Common stock, shares outstanding	17,507,283	17,483,283
Common stock to be issued, par value	$ 0.001	$ 0.001
Common stock to be issued, shares outstanding	12,607,281	651,281
Series A Preferred Stock [Member]
Preferred stock par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	3,000,000	3,000,000
Preferred stock, shares issued	0	3,000,000
Preferred stock, shares outstanding	0	3,000,000
Series B Preferred Stock [Member]
Preferred stock par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	4,440,000	4,440,000
Preferred stock, shares issued	0	4,440,000
Preferred stock, shares outstanding	0	4,440,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Income Statement [Abstract]
Revenues
Operating Expenses:
Personnel costs	23,072	59,756	68,532	252,487
Research and development expenses, related party			7,243	94,048
Professional fees	79,465	15,925	130,828	302,259
General and administrative expenses	8,644	13,540	26,410	36,501
Total operating expenses	111,181	89,221	233,013	685,295
Loss from operations	(111,181)	(89,221)	(233,013)	(685,295)
Other income:
Other income			100,000
Total other income			100,000
Loss before income taxes	(111,181)	(89,221)	(133,013)	(685,295)
Income taxes
Net loss available to common shareholders	$ (111,181)	$ (89,221)	$ (133,013)	$ (685,295)
Loss per share basic and fully diluted	$ (0.01)	$ (0.01)	$ (0.01)	$ (0.04)
Basic and diluted weighted average common shares outstanding	17,507,283	17,483,283	17,503,591	17,483,283

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($)	Series A Preferred Stock [Member]Preferred Stock [Member]	Series B Preferred Stock [Member]Preferred Stock [Member]	Common Stock [Member]	Common Stock to be Issued [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2019	$ 3,000	$ 4,440	$ 17,483	$ 651	$ 13,403,293	$ (13,126,910)	$ 301,957
Beginning balance, shares at Dec. 31, 2019	3,000,000	4,440,000	17,483,283	651,281
Net income (loss)						(364,459)	(364,459)
Ending balance, value at Mar. 31, 2020	$ 3,000	$ 4,440	$ 17,483	$ 651	13,403,293	(13,491,369)	(62,502)
Beginning balance, shares at Mar. 31, 2020	3,000,000	4,440,000	17,483,283	651,281
Beginning balance, value at Dec. 31, 2019	$ 3,000	$ 4,440	$ 17,483	$ 651	13,403,293	(13,126,910)	301,957
Beginning balance, shares at Dec. 31, 2019	3,000,000	4,440,000	17,483,283	651,281
Net income (loss)							(685,295)
Ending balance, value at Sep. 30, 2020	$ 3,000	$ 8,880	$ 17,483	$ 651	13,416,992	(13,812,205)	(369,639)
Beginning balance, shares at Sep. 30, 2020	3,000,000	4,440,000	17,483,283	651,281
Beginning balance, value at Mar. 31, 2020	$ 3,000	$ 4,440	$ 17,483	$ 651	13,403,293	(13,491,369)	(62,502)
Beginning balance, shares at Mar. 31, 2020	3,000,000	4,440,000	17,483,283	651,281
Net income (loss)						(231,614)	(231,614)
Ending balance, value at Jun. 30, 2020	$ 3,000	$ 8,880	$ 17,483	$ 651	13,403,293	(13,722,983)	(294,116)
Beginning balance, shares at Jun. 30, 2020	3,000,000	4,440,000	17,483,283	651,281
Net income (loss)						(89,222)	(89,222)
Stock-based compensation expense					13,699		13,699
Ending balance, value at Sep. 30, 2020	$ 3,000	$ 8,880	$ 17,483	$ 651	13,416,992	(13,812,205)	(369,639)
Beginning balance, shares at Sep. 30, 2020	3,000,000	4,440,000	17,483,283	651,281
Beginning balance, value at Dec. 31, 2020	$ 3,000	$ 4,440	$ 17,483	$ 651	13,418,074	(13,892,754)	(449,106)
Beginning balance, shares at Dec. 31, 2020	3,000,000	4,440,000	17,483,283	651,281
Conversion of Series A Preferred Stock to common stock to be issued	$ (3,000)			$ 6,000	(3,000)
Beginning balance, shares	(3,000,000)			6,000,000
Conversion of Series B Preferred Stock to common stock		$ (4,440)		$ 4,440
Beginning balance, shares		(4,440,000)		4,440,000
Common stock issued for common stock to be issued			$ 24	$ (24)
Beginning balance, shares			24,000	(24,000)
Net income (loss)						50,230	50,230
Stock-based compensation expense					1,082		1,082
Ending balance, value at Mar. 31, 2021			$ 17,507	$ 11,067	13,416,156	(13,842,524)	(397,794)
Beginning balance, shares at Mar. 31, 2021			17,507,283	11,067,281
Beginning balance, value at Dec. 31, 2020	$ 3,000	$ 4,440	$ 17,483	$ 651	13,418,074	(13,892,754)	(449,106)
Beginning balance, shares at Dec. 31, 2020	3,000,000	4,440,000	17,483,283	651,281
Net income (loss)							(133,013)
Ending balance, value at Sep. 30, 2021			$ 17,507	$ 12,607	13,801,778	(14,025,767)	(193,875)
Beginning balance, shares at Sep. 30, 2021			17,507,283	12,607,281
Beginning balance, value at Mar. 31, 2021			$ 17,507	$ 11,067	13,416,156	(13,842,524)	(397,794)
Beginning balance, shares at Mar. 31, 2021			17,507,283	11,067,281
Sale of common stock for cash				$ 840	209,160		210,000
Beginning balance, shares				840,000
Net income (loss)						(72,062)	(72,062)
Stock-based compensation expense					1,081		1,081
Ending balance, value at Jun. 30, 2021			$ 17,507	$ 11,907	13,626,397	(13,914,586)	(258,775)
Beginning balance, shares at Jun. 30, 2021			17,507,283	11,907,281
Sale of common stock for cash				$ 700	174,300		175,000
Beginning balance, shares				700,000
Net income (loss)						(111,181)	(111,181)
Stock-based compensation expense					1,081		1,081
Ending balance, value at Sep. 30, 2021			$ 17,507	$ 12,607	$ 13,801,778	$ (14,025,767)	$ (193,875)
Beginning balance, shares at Sep. 30, 2021			17,507,283	12,607,281

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Cash Flows from Operating Activities:
Net loss	$ (133,013)	$ (685,295)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization	23,466	23,587
Stock-based compensation	3,244	13,699
Gain on sale of equity method investment	(100,000)
Changes in operating assets and liabilities:
Prepaid Expenses	(7,240)	(1,942)
Accounts payable	(5,177)	81,579
Accounts payable, related parties	(102,000)	190,548
Accrued salaries, related party		115,312
Net Cash Used in Operating Activities	(320,720)	(262,512)
Cash Flows from Investing Activities:
Proceeds from sale of equity method investment	100,000
Net Cash Used in Investing Activities	100,000
Cash Flows from Financing Activities:
Proceeds from sale of common stock	385,000
Net Cash Provided By Financing Activities	385,000
Net Increase (decrease) in Cash	164,280	(262,512)
Cash, Beginning of period	1,269	264,166
Cash, End of period	$ 165,549	$ 1,654

ORGANIZATION

ORGANIZATION	9 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
ORGANIZATION	NOTE 1 - ORGANIZATION Business Vicapsys Life Sciences, Inc. (“VLS”) was incorporated in the State of Florida on July 8, 1997 under the name All Product Distribution Corp. On August 19, 1998, the Company changed its name to Phage Therapeutics International, Inc. On November 13, 2007, the Company changed its name to SSGI, Inc. On September 13, 2017, the Company changed its name to Vicapsys Life Sciences, Inc., effected a 1-for-100 reverse stock split of its outstanding common stock, increased the Company’s authorized capital stock to 300,000,000 0.001 20,000,000 0.001 The Company’s strategy is to develop and commercialize, on a worldwide basis, various intellectual property rights (patents, patent applications, know how, etc.) relating to a series of encapsulated products that incorporate proprietary derivatives of the chemokine CXCL12 for creating a zone of immunoprotection around cells, tissues, organs and devices for therapeutic purposes. The product name VICAPSYN™ is the Company’s proprietary product line that is applied to transplantation therapies and related stem-cell applications in the transplantation field.

GOING CONCERN AND MANAGEMENT_S

GOING CONCERN AND MANAGEMENT’S PLANS	9 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GOING CONCERN AND MANAGEMENT’S PLANS	NOTE 2 – GOING CONCERN AND MANAGEMENT’S PLANS The accompanying unaudited condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which assumes the realization of assets and satisfaction of liabilities and commitments in the normal course of business. The Company experienced a net loss of $ 133,013 580,498 14,025,767 In March 2020, the World Health Organization declared the novel COVID-19 virus as a global pandemic. The COVID-19 outbreak in the United States has resulted in a significant impact to the Company’s ability to secure additional debt or equity funding to support operations in 2020. In 2021, the Company raised $ 385,000 1,540,000 125,000

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING PRINCIPLES	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING PRINCIPLES	NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING PRINCIPLES Basis of Presentation and Principles of Consolidation The accompanying condensed consolidated financial statements in this report have been prepared by the Company without audit. In the opinion of management, all adjustments necessary to present the financial position, results of operations and cash flows for the stated periods have been made. Except as described below, these adjustments consist only of normal and recurring adjustments. Certain information and note disclosures normally included in the Company’s consolidated annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. These unaudited condensed consolidated financial statements should be read in conjunction with a reading of the Company’s consolidated audited financial statements and notes thereto for the year ended December 31, 2020, filed on Form 10-K with the Securities and Exchange Commission on September 17, 2021. Interim results of operations for the three and nine months ended September 30, 2021, and 2020, are not necessarily indicative of future results for the full year. The unaudited condensed consolidated financial statements of the Company include the consolidated accounts of VLS and its’ wholly owned subsidiary VI. All intercompany accounts and transactions have been eliminated in consolidation. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reported period. Actual results could differ from those estimates. Significant estimates included in the financial statements, include useful the life of intangible assets, valuation allowance for deferred tax assets and non-cash equity transactions and stock-based compensation. Cash The Company considers all highly liquid investments with an original term of three months or less to be cash equivalents. The Company held no Intangible Assets Costs of intangible assets are accounted for through the capitalization of those costs incurred in connection with developing or obtaining such assets. Capitalized costs are included in intangible assets in the unaudited condensed consolidated balance sheets. The Company’s intangible assets consist of costs incurred in connection with securing an Exclusive Patent License Agreement with The General Hospital Corporation, d/b/a Massachusetts General Hospital (“MGH”), as amended (the “License Agreement”). These costs are being amortized over the term of the License Agreement which is based on the remaining life of the related patents being licensed. The Company reviews these intangible assets for possible impairment when events or changes in circumstances indicate that the assets carrying amount may not be recoverable. In evaluating the future benefit of its intangible assets, management performs an analysis of the anticipated undiscounted future net cash flows of the intangible assets over the remaining estimated useful life. An impairment loss is recorded if the carrying value of the asset exceeds the expected future cash flows. Long-Lived Assets The Company reviews long-lived assets at least annually or when events or changes in circumstances reflect the fact that the recorded value may not be recoverable for impairment and recognizes impairment losses on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying values. Equity Method Investment The Company accounts for investments in which the Company owns more than 20 Investments—Equity Method and Joint Ventures The amount of the adjustment is included in the determination of net income by the investor, and such amount reflects adjustments similar to those made in preparing consolidated statements including adjustments to eliminate intercompany gains and losses, and to amortize, if appropriate, any difference between investor cost and underlying equity in net assets of the investee at the date of investment. The investment of an investor is also adjusted to reflect the investor’s share of changes in the investee’s capital. Dividends received from an investee reduce the carrying amount of the investment. A series of operating losses of an investee or other factors may indicate that a decrease in value of the investment has occurred which is other than temporary, and which should be recognized even though the decrease in value is in excess of what would otherwise be recognized by application of the equity method. In accordance with ASC 323-10-35-20 through 35-22, the investor ordinarily shall discontinue applying the equity method if the investment (and net advances) is reduced to zero and shall not provide for additional losses unless the investor has guaranteed obligations of the investee or is otherwise committed to provide further financial support for the investee. An investor shall, however, provide for additional losses if the imminent return to profitable operations by an investee appears to be assured. For example, a material, nonrecurring loss of an isolated nature may reduce an investment below zero even though the underlying profitable operating pattern of an investee is unimpaired. If the investee subsequently reports net income, the investor shall resume applying the equity method only after its share of that net income equals the share of net losses not recognized during the period the equity method was suspended. Equity and cost method investments are classified as investments. The Company periodically evaluates its equity and cost method investments for impairment due to declines considered to be other than temporary. If the Company determines that a decline in fair value is other than temporary, then a charge to earnings is recorded as an impairment loss in the accompanying consolidated statements of operations. The Company’s equity method investment consisted of equity owned in Athens Encapsulation Inc. (“AEI”), a Company controlled by former directors of the Company which was given to the Company as part of an investment and restructuring agreement entered into in May 2019. In January 2021, the Company sold its’ equity investment in AEI, back to AEI for $ 100,000 , which is included in gain on sale of equity method investment for the nine months ended September 30, 2021. As of September 30, 2021, the Company did not have any remaining equity investment in AEI. During the three and nine months ended September 30, 2021, and 2020, the Company’s proportionate share of net income was insignificant. Fair Value of Financial Instruments ASC 825, “Disclosures about Fair Value of Financial Instruments,” requires disclosure of fair value information about financial instruments. ASC 820, “Fair Value Measurements” defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles, and expands disclosures about fair value measurements. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of September 30, 2021. The carrying amounts of the Company’s financial assets and liabilities, such as cash, prepaid expenses, accounts payable and accrued liabilities, payables with related parties, approximate their fair values because of the short maturity of these instruments. Revenue Recognition Revenue recognition is accounted for under ASC Topic 606, “Revenue from Contracts with Customers” (“ASC 606”) and all the related amendments. The core principle of ASC 606 requires that an entity recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. ASC 606 defines a five-step process to achieve this core principle and, in doing so, it is possible more judgment and estimates may be required within the revenue recognition process than required under U.S. GAAP including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. The Company’s contracts with customers are generally on a contract and work order basis and represent obligations that are satisfied at a point in time, as defined in the new guidance, generally upon delivery or has services are provided. Accordingly, revenue for each sale is recognized when the Company has completed its performance obligations. Any costs incurred before this point in time, are recorded as assets to be expensed during the period the related revenue is recognized. The Company did not generate any revenue for the three and nine months ended September 30, 2021, and 2020. Stock-Based Compensation Stock-based compensation is accounted for based on the requirements of ASC 718 – “Compensation –Stock Compensation, Improvements to Employee Share-Based Payment Research and Development Costs and expenses that can be clearly identified as research and development are charged to expense as incurred. For the three and nine months ended September 30, 2021, the Company incurred $-0- and $ 7,243 94,048 Income Taxes The Company accounts for income taxes in accordance with ASC 740-10, Income Taxes. Deferred tax assets and liabilities are recognized to reflect the estimated future tax effects, calculated at the tax rate expected to be in effect at the time of realization. A valuation allowance related to a deferred tax asset is recorded when it is more likely than not that some portion of the deferred tax asset will not be realized. Deferred tax assets and liabilities are adjusted for the effects of the changes in tax laws and rates of the date of enactment. ASC 740-10 prescribes a recognition threshold that a tax position is required to meet before being recognized in the financial statements and provides guidance on recognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition issues. Interest and penalties are classified as a component of interest and other expenses. To date, the Company has not been assessed, nor paid, any interest or penalties. Uncertain tax positions are measured and recorded by establishing a threshold for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Only tax positions meeting the more-likely-than-not recognition threshold at the effective date may be recognized or continue to be recognized. Earnings (Loss) Per Share The Company reports earnings (loss) per share in accordance with ASC 260, “Earnings per Share.” Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding during each period. Diluted earnings per share is computed by dividing net loss by the weighted-average number of shares of common stock, common stock equivalents and other potentially dilutive securities outstanding during the period. As of September 30, 2021, and 2020, the Company’s dilutive securities are convertible into 23,467,283 17,431,756 The following table represents the classes of dilutive securities as of September 30, 2021, and 2020: SCHEDULE OF ANTIDILUTIVE SECURITIES OF EARNINGS PER SHARE September 30, 2021 September 30, 2020 Common stock to be issued 17,507,283 651,281 Convertible preferred stock - 10,440,000 Stock options 1,900,000 2,193,750 Warrants to purchase common stock 4,060,000 4,146,725 23,467,283 17,431,756 Recent Accounting Pronouncements Management does not believe that any recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the accompanying unaudited condensed consolidated financial statements for the three and nine months ended September 30, 2021, and 2020.

INTANGIBLE ASSETS

INTANGIBLE ASSETS	9 Months Ended
	Sep. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS	NOTE 4 – INTANGIBLE ASSETS The Company’s intangible assets consist of costs incurred in connection with the License Agreement with MGH, as amended (See Note 5). The consideration paid for the rights included in the License Agreement was in the form of common stock shares which resulted in MGH receiving approximately 20 16 The Company’s intangible assets consisted of the following at September 30, 2021, and December 31, 2020: SCHEDULE OF INTANGIBLE ASSETS September 30, 2021 December 31, 2020 Licensed patents $ 492,514 $ 492,514 Accumulated amortization (113,132 ) (89,665 ) Balance $ 379,382 $ 402,849 The Company recognized $ 7,823 23,467 7,862 23,587 Future expected amortization of intangible assets is as follows: SCHEDULE OF FUTURE AMORTIZATION OF INTANGIBLE ASSETS Fiscal year ending December 31, 2021 (months remaining) $ 7,823 2022 31,299 2023 31,299 2024 31,299 2025 31,299 Thereafter 246,363 Balance $ 379,382

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	9 Months Ended
	Sep. 30, 2021
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 5 – RELATED PARTY TRANSACTIONS Consulting Agreement On June 21, 2019, the Company entered into a Consulting Agreement (the “Consulting Agreement”) with Mark Poznansky, MD, (the “Consultant”) a minority stockholder and former Director. The Company engaged the Consultant to render consulting services with respect to informing, guiding and supervising the development of antagonists to immune repellents or anti-fugetaxins for the treatment of cancer. The initial term of the Consulting Agreement is for one year (the “Initial Term”) and the Company agreed to pay the Consultant $ 3,000 6,000 st 5 0 18,000 9,000 MGH License Agreement On May 8, 2013, VI and MGH, a principal stockholder (see Note 6) entered into the License Agreement, pursuant to which MGH granted to the Company, in the field of coating and transplanting cells, tissues and devices for therapeutic purposes, on a worldwide basis: (i) an exclusive, royalty-bearing license under its rights in Patent Rights (as defined in the License Agreement) to make, use, sell, lease, import and transfer Products and Processes (each as defined in the License Agreement); (ii) a non-exclusive, sub-licensable (solely in the License Field and License Territory (each as defined in the License Agreement)) royalty-bearing license to Materials (as defined in the License Agreement) and to make, have made, use, have used, Materials for only the purpose of creating Products, the transfer of Products and to use, have used and transfer processes; (iii) the right to grant sublicenses subject to and in accordance with the terms of the License Agreement, and (iv) the nonexclusive right to use technological information (as defined in the License Agreement) disclosed by MGH to the Company under the License Agreement, all subject to and in accordance with the License Agreement (the “License”). As amended by the Seventh Amendment to the License Agreement on December 22, 2017, the License Agreement requires that VI satisfy the following requirements prior to the first sale of Products (“MGH License Milestones”), by certain dates which have passed. The table below lists the MGH Milestones and the Company’s progress in satisfying or negotiating the extension of each milestone: MILESTONE: STATUS: (i) Provide a detailed business and development plan. The Company has provided MGH with a completed Corporate pitch deck which outlines the Company’s business and development plans has been provided to MGH. (ii) Raise $ 2 The Company has raised $1 million and is currently in the process of raising the second $1 million. The Company and MGH are currently negotiating extending this milestone (iii) Initiate and finance research regarding the role of CXCL12 in minimizing fibrosis formation. Milestone completed. (iv) Initiate and finance research regarding the role of CXCL12 in beta cell function and differentiation. Dr. Poznansky’s lab was focusing on this as part of the academic project. The Company therefore made the strategic decision to fund another aspect of CXCL12 biology which focuses on the role of CXCL12 in wound healing. For the time being, the Company is excused from meeting this milestone as it has provided an alternative milestone as well as a justification for not pursuing this particular milestone. The Company and MGH have agreed to work together to restate the License Agreement, incorporating all the relevant provisions from the seven amendments and agreeing on a new set of milestones for future development. The License Agreement also requires VI to pay to MGH a one percent ( 1 The License Agreement additionally requires VI to pay to MGH a $1.0 million “success payment” within 60 days after the first achievement of total net sales of Product or Process equal to or to exceed $100,000,000 in any calendar year and $4,000,000 within sixty (60) days after the first achievement of total net sales of Product or Process equal or exceed $250,000,000 in any calendar year. The Company is also required to reimburse MGH’s expenses in connection with the preparation, filing, prosecution and maintenance of all Patent Rights The License Agreement expires on the later of (i) the date on which all issued patents and filed patent applications within the Patent Rights have expired or been abandoned, and (ii) one (1) year after the last sale for which a royalty is due under the License Agreement. The License Agreement also grants MGH the right to terminate the License Agreement if VI fails to make any payment due under the License Agreement or defaults in the performance of any of its other obligations under the License Agreement, subject to certain notice and rights to cure set forth therein. MGH may also terminate the License Agreement immediately upon written notice to VI if VI: (i) shall make an assignment for the benefit of creditors; or (ii) or shall have a petition in bankruptcy filed for or against it that is not dismissed within sixty (60) days of filing. As of the date of this filing, this License Agreement remains active and the Company has not received any termination notice from MGH. VI may terminate the License Agreement prior to its expiration by giving ninety (90) days’ advance written notice to MGH, and upon such termination shall, subject to the terms of the License Agreement, immediately cease all use and sales of Products and Processes. The Company incurred costs to MGH of $- 0 7,243 0 94,048 0 101,180 During the three and nine months ended September 30, 2021, and 2020, there have not been any sales of Product or Process under this License Agreement. Accounts Payable, related parties and Accrued Salaries, related party The Company incurred director fees of $ 22,500 67,500 75,000 67,500 The Company incurred consulting fees of $ 15,000 45,000 50,180 45,000 In August 2020, Frances Tonneguzzo, the Company’s Chief Executive Officer (the “former CEO”) tendered her resignation as CEO. For the three and nine months ended September 30, 2021, the Company did not incur any expenses and for the three and nine months ended September 30, 2020, the Company incurred expenses of $ 35,554 172,354 115,312 Sale of Equity Method Investment In January 2021, the Company sold its’ equity investment in AEI back to AEI for $ 100,000

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 6– COMMITMENTS AND CONTINGENCIES Legal Matters The Company is not aware of any material, existing or pending legal proceedings against our Company, nor are we involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which any of our directors, officers or affiliates, or any registered or beneficial shareholder, is an adverse party or has a material interest adverse to our interest. MGH License Agreement As discussed in Note 5, the Company executed a License Agreement with MGH. The License Agreement also requires VI to pay to MGH a one percent ( 1 The License Agreement additionally requires VI to pay to MGH a $ 1.0 Consulting Agreement On June 21, 2019, the Company entered into a Consulting Agreement (the “Consulting Agreement”) with C&H Capital, Inc. (the “Consultant”). The Company engaged the Consultant to render consulting services to facilitate long range strategic investor relations planning and other related services. The initial term of the Consulting Agreement is for one year 3,500 0 21,000 50,000 0.25 14,000

STOCKHOLDERS_ EQUITY (DEFICIT)

STOCKHOLDERS’ EQUITY (DEFICIT)	9 Months Ended
	Sep. 30, 2021
Equity [Abstract]
STOCKHOLDERS’ EQUITY (DEFICIT)	NOTE 7 – STOCKHOLDERS’ EQUITY (DEFICIT) Preferred Stock The Company has 20,000,000 0.001 Series A Preferred Stock On December 19, 2017, the Company amended its articles of incorporation by filing a certificate of designation with the Secretary of State of Florida therein designating a class of preferred stock as Series A Preferred Stock, $ 0.001 3,000,000 Each holder of shares of Series A Preferred Stock shall be entitled to the number of votes equal to the number of votes held by the number of shares of common stock into which such share of Series A Preferred Stock could be converted, and except as otherwise required by applicable law, shall have the voting rights and power equal to the voting rights and powers of the common stock 1.67 Each share of Series A Preferred Stock is convertible into shares of common stock at a conversion Rate of 2:1 (the “Series A Conversion Rate”) Pursuant to the Articles of Incorporation, the shares of Series A Preferred Stock automatically converted into 6,000,000 As of September 30, 2021, and December 31, 2020, there were - 0 3,000,000 Series B Preferred Stock On December 19, 2017, the Company amended the articles of incorporation by filing a certificate of designation with the Secretary of State of Florida therein designating a class of preferred stock as Series B Preferred Stock, $ 0.001 4,440,000 Each holder of shares of Series B Preferred Stock shall be entitled to the number of votes equal to the number of votes held by the number of shares of common stock into which such share of Series B Preferred Stock could be converted, and except as otherwise required by applicable law, shall have the voting rights and power equal to the voting rights and powers of the common stock 0.83 The holder of Series B Preferred Stock may elect at any time to convert such sharers into common stock of the Company. Each share of Series B Preferred Stock is convertible into shares of common stock at a conversion rate of 1:1 (the “Series B Conversion Rate”) Pursuant to the Articles of Incorporation, the shares of Series B Preferred Stock automatically converted into 4,440,000 As of September 30, 2021, and December 31, 2020, there were - 0 4,440,000 Common Stock The Company has 300,000,000 0.001 17,561,550 17,483,283 Common Stock Issuances On February 12, 2021, the Company issued 6,000,000 On February 12, 2021, the Company issued 4,440,000 During the nine months ended September 30, 2021, the Company sold 1,540,000 0.25 385,000 Common Stock to be issued On February 12, 2021, the Company recorded 6,000,000 On February 12, 2021, the Company recorded 4,440,000 As of September 30, 2021, and December 31, 2020, there were 17,507,283 651,281 6,000,000 4,440,000 1,540,000 597,281 1.85 30,000 621,281 30,000 Stock Options The following table summarizes activities related to stock options of the Company for the nine months ended September 30, 2021: SCHEDULE OF STOCK OPTIONS ACTIVITY Number of Weighted- Weighted- (Years) Outstanding at December 31, 2020 1,900,000 $ 0.66 6.83 Outstanding at September 30, 2021 1,900,000 $ 0.66 6.08 Exercisable at September 30, 2021 1,875,000 $ 0.67 6.06 The Company did not grant any options to purchase shares of common stock during the nine months ended September 30, 2021. The Company recorded stock compensation expense of $ 1,081 and $ 3,244 for the three and nine months ended September 30, 2021, respectively, and $ 2,883 and $ 13,699 for the three and nine months ended September 30, 2020, respectively. As of September 30, 2021, 25,000 options to purchase shares of common stock remain unvested and $ 3,245 of stock compensation expense remains unrecognized and will be expensed over a weighted average period of 0.50 years. Warrants The following table summarizes activities related to warrants of the Company for the nine months ended September 30, 2021: SCHEDULE OF WARRANTS ACTIVITY Number of Weighted- Weighted- (Years) Outstanding and exercisable at December 31, 2020 4,146,725 $ 0.53 1.50 Expired 86,725 1.85 Outstanding and exercisable at September 30, 2021 4,060,000 $ 0.50 0.76 The Company did not issue any warrants during the nine months ended September 30, 2021.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Sep. 30, 2021
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 8 – SUBSEQUENT EVENTS In June 2021, the Company entered into Security Purchase Agreements (“SPA’s) with select accredited investors in connection with a private offering by the Company to raise a maximum of $ 1,000,000 0.25 125,000

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING PRINCIPLES (Policies)	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The accompanying condensed consolidated financial statements in this report have been prepared by the Company without audit. In the opinion of management, all adjustments necessary to present the financial position, results of operations and cash flows for the stated periods have been made. Except as described below, these adjustments consist only of normal and recurring adjustments. Certain information and note disclosures normally included in the Company’s consolidated annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. These unaudited condensed consolidated financial statements should be read in conjunction with a reading of the Company’s consolidated audited financial statements and notes thereto for the year ended December 31, 2020, filed on Form 10-K with the Securities and Exchange Commission on September 17, 2021. Interim results of operations for the three and nine months ended September 30, 2021, and 2020, are not necessarily indicative of future results for the full year. The unaudited condensed consolidated financial statements of the Company include the consolidated accounts of VLS and its’ wholly owned subsidiary VI. All intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reported period. Actual results could differ from those estimates. Significant estimates included in the financial statements, include useful the life of intangible assets, valuation allowance for deferred tax assets and non-cash equity transactions and stock-based compensation.
Cash	Cash The Company considers all highly liquid investments with an original term of three months or less to be cash equivalents. The Company held no
Intangible Assets	Intangible Assets Costs of intangible assets are accounted for through the capitalization of those costs incurred in connection with developing or obtaining such assets. Capitalized costs are included in intangible assets in the unaudited condensed consolidated balance sheets. The Company’s intangible assets consist of costs incurred in connection with securing an Exclusive Patent License Agreement with The General Hospital Corporation, d/b/a Massachusetts General Hospital (“MGH”), as amended (the “License Agreement”). These costs are being amortized over the term of the License Agreement which is based on the remaining life of the related patents being licensed. The Company reviews these intangible assets for possible impairment when events or changes in circumstances indicate that the assets carrying amount may not be recoverable. In evaluating the future benefit of its intangible assets, management performs an analysis of the anticipated undiscounted future net cash flows of the intangible assets over the remaining estimated useful life. An impairment loss is recorded if the carrying value of the asset exceeds the expected future cash flows.
Long-Lived Assets	Long-Lived Assets The Company reviews long-lived assets at least annually or when events or changes in circumstances reflect the fact that the recorded value may not be recoverable for impairment and recognizes impairment losses on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying values.
Equity Method Investment	Equity Method Investment The Company accounts for investments in which the Company owns more than 20 Investments—Equity Method and Joint Ventures The amount of the adjustment is included in the determination of net income by the investor, and such amount reflects adjustments similar to those made in preparing consolidated statements including adjustments to eliminate intercompany gains and losses, and to amortize, if appropriate, any difference between investor cost and underlying equity in net assets of the investee at the date of investment. The investment of an investor is also adjusted to reflect the investor’s share of changes in the investee’s capital. Dividends received from an investee reduce the carrying amount of the investment. A series of operating losses of an investee or other factors may indicate that a decrease in value of the investment has occurred which is other than temporary, and which should be recognized even though the decrease in value is in excess of what would otherwise be recognized by application of the equity method. In accordance with ASC 323-10-35-20 through 35-22, the investor ordinarily shall discontinue applying the equity method if the investment (and net advances) is reduced to zero and shall not provide for additional losses unless the investor has guaranteed obligations of the investee or is otherwise committed to provide further financial support for the investee. An investor shall, however, provide for additional losses if the imminent return to profitable operations by an investee appears to be assured. For example, a material, nonrecurring loss of an isolated nature may reduce an investment below zero even though the underlying profitable operating pattern of an investee is unimpaired. If the investee subsequently reports net income, the investor shall resume applying the equity method only after its share of that net income equals the share of net losses not recognized during the period the equity method was suspended. Equity and cost method investments are classified as investments. The Company periodically evaluates its equity and cost method investments for impairment due to declines considered to be other than temporary. If the Company determines that a decline in fair value is other than temporary, then a charge to earnings is recorded as an impairment loss in the accompanying consolidated statements of operations. The Company’s equity method investment consisted of equity owned in Athens Encapsulation Inc. (“AEI”), a Company controlled by former directors of the Company which was given to the Company as part of an investment and restructuring agreement entered into in May 2019. In January 2021, the Company sold its’ equity investment in AEI, back to AEI for $ 100,000 , which is included in gain on sale of equity method investment for the nine months ended September 30, 2021. As of September 30, 2021, the Company did not have any remaining equity investment in AEI. During the three and nine months ended September 30, 2021, and 2020, the Company’s proportionate share of net income was insignificant.
Fair Value of Financial Instruments	Fair Value of Financial Instruments ASC 825, “Disclosures about Fair Value of Financial Instruments,” requires disclosure of fair value information about financial instruments. ASC 820, “Fair Value Measurements” defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles, and expands disclosures about fair value measurements. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of September 30, 2021. The carrying amounts of the Company’s financial assets and liabilities, such as cash, prepaid expenses, accounts payable and accrued liabilities, payables with related parties, approximate their fair values because of the short maturity of these instruments.
Revenue Recognition	Revenue Recognition Revenue recognition is accounted for under ASC Topic 606, “Revenue from Contracts with Customers” (“ASC 606”) and all the related amendments. The core principle of ASC 606 requires that an entity recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. ASC 606 defines a five-step process to achieve this core principle and, in doing so, it is possible more judgment and estimates may be required within the revenue recognition process than required under U.S. GAAP including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. The Company’s contracts with customers are generally on a contract and work order basis and represent obligations that are satisfied at a point in time, as defined in the new guidance, generally upon delivery or has services are provided. Accordingly, revenue for each sale is recognized when the Company has completed its performance obligations. Any costs incurred before this point in time, are recorded as assets to be expensed during the period the related revenue is recognized. The Company did not generate any revenue for the three and nine months ended September 30, 2021, and 2020.
Stock-Based	Stock-Based Compensation Stock-based compensation is accounted for based on the requirements of ASC 718 – “Compensation –Stock Compensation, Improvements to Employee Share-Based Payment
Research and Development	Research and Development Costs and expenses that can be clearly identified as research and development are charged to expense as incurred. For the three and nine months ended September 30, 2021, the Company incurred $-0- and $ 7,243 94,048
Income Taxes	Income Taxes The Company accounts for income taxes in accordance with ASC 740-10, Income Taxes. Deferred tax assets and liabilities are recognized to reflect the estimated future tax effects, calculated at the tax rate expected to be in effect at the time of realization. A valuation allowance related to a deferred tax asset is recorded when it is more likely than not that some portion of the deferred tax asset will not be realized. Deferred tax assets and liabilities are adjusted for the effects of the changes in tax laws and rates of the date of enactment. ASC 740-10 prescribes a recognition threshold that a tax position is required to meet before being recognized in the financial statements and provides guidance on recognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition issues. Interest and penalties are classified as a component of interest and other expenses. To date, the Company has not been assessed, nor paid, any interest or penalties. Uncertain tax positions are measured and recorded by establishing a threshold for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Only tax positions meeting the more-likely-than-not recognition threshold at the effective date may be recognized or continue to be recognized.
Earnings (Loss) Per Share	Earnings (Loss) Per Share The Company reports earnings (loss) per share in accordance with ASC 260, “Earnings per Share.” Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding during each period. Diluted earnings per share is computed by dividing net loss by the weighted-average number of shares of common stock, common stock equivalents and other potentially dilutive securities outstanding during the period. As of September 30, 2021, and 2020, the Company’s dilutive securities are convertible into 23,467,283 17,431,756 The following table represents the classes of dilutive securities as of September 30, 2021, and 2020: SCHEDULE OF ANTIDILUTIVE SECURITIES OF EARNINGS PER SHARE September 30, 2021 September 30, 2020 Common stock to be issued 17,507,283 651,281 Convertible preferred stock - 10,440,000 Stock options 1,900,000 2,193,750 Warrants to purchase common stock 4,060,000 4,146,725 23,467,283 17,431,756
Recent Accounting Pronouncements	Recent Accounting Pronouncements Management does not believe that any recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the accompanying unaudited condensed consolidated financial statements for the three and nine months ended September 30, 2021, and 2020.

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING PRINCIPLES (Tables)	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
SCHEDULE OF ANTIDILUTIVE SECURITIES OF EARNINGS PER SHARE	The following table represents the classes of dilutive securities as of September 30, 2021, and 2020: SCHEDULE OF ANTIDILUTIVE SECURITIES OF EARNINGS PER SHARE September 30, 2021 September 30, 2020 Common stock to be issued 17,507,283 651,281 Convertible preferred stock - 10,440,000 Stock options 1,900,000 2,193,750 Warrants to purchase common stock 4,060,000 4,146,725 23,467,283 17,431,756

INTANGIBLE ASSETS (Tables)

INTANGIBLE ASSETS (Tables)	9 Months Ended
	Sep. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
SCHEDULE OF INTANGIBLE ASSETS	The Company’s intangible assets consisted of the following at September 30, 2021, and December 31, 2020: SCHEDULE OF INTANGIBLE ASSETS September 30, 2021 December 31, 2020 Licensed patents $ 492,514 $ 492,514 Accumulated amortization (113,132 ) (89,665 ) Balance $ 379,382 $ 402,849
SCHEDULE OF FUTURE AMORTIZATION OF INTANGIBLE ASSETS	Future expected amortization of intangible assets is as follows: SCHEDULE OF FUTURE AMORTIZATION OF INTANGIBLE ASSETS Fiscal year ending December 31, 2021 (months remaining) $ 7,823 2022 31,299 2023 31,299 2024 31,299 2025 31,299 Thereafter 246,363 Balance $ 379,382

STOCKHOLDERS_ EQUITY (DEFICIT)

STOCKHOLDERS’ EQUITY (DEFICIT) (Tables)	9 Months Ended
	Sep. 30, 2021
Equity [Abstract]
SCHEDULE OF STOCK OPTIONS ACTIVITY	The following table summarizes activities related to stock options of the Company for the nine months ended September 30, 2021: SCHEDULE OF STOCK OPTIONS ACTIVITY Number of Weighted- Weighted- (Years) Outstanding at December 31, 2020 1,900,000 $ 0.66 6.83 Outstanding at September 30, 2021 1,900,000 $ 0.66 6.08 Exercisable at September 30, 2021 1,875,000 $ 0.67 6.06
SCHEDULE OF WARRANTS ACTIVITY	The following table summarizes activities related to warrants of the Company for the nine months ended September 30, 2021: SCHEDULE OF WARRANTS ACTIVITY Number of Weighted- Weighted- (Years) Outstanding and exercisable at December 31, 2020 4,146,725 $ 0.53 1.50 Expired 86,725 1.85 Outstanding and exercisable at September 30, 2021 4,060,000 $ 0.50 0.76

ORGANIZATION (Details Narrative

ORGANIZATION (Details Narrative) - $ / shares	Sep. 13, 2017	Sep. 30, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Reverse stock split	On September 13, 2017, the Company changed its name to Vicapsys Life Sciences, Inc., effected a 1-for-100 reverse stock split of its outstanding common stock, increased the Company’s authorized capital stock to 300,000,000 shares of common stock, par value $0.001 per share, and 20,000,000 shares of “blank check” preferred stock, par value $0.001 per share
Common stock, shares authorized	300,000,000	300,000,000	300,000,000
Common stock, par value	$ 0.001	$ 0.001	$ 0.001
Preferred stock, shares authorized	20,000,000	20,000,000	20,000,000
Preferred stock, par value	$ 0.001	$ 0.001	$ 0.001

GOING CONCERN AND MANAGEMENT__2

GOING CONCERN AND MANAGEMENT’S PLANS (Details Narrative) - USD ($)	Oct. 01, 2021	Sep. 30, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Subsequent Event [Line Items]
Net loss			$ 111,181	$ 72,062	$ (50,230)	$ 89,222	$ 231,614	$ 364,459	$ 133,013	$ 685,295
Working capital		$ 580,498	580,498						580,498
Accumulated deficit		14,025,767	$ 14,025,767						14,025,767		$ 13,892,754
Proceeds from sale of common stock		$ 385,000							$ 385,000
Number of shares issued		1,540,000
Subsequent Event [Member]
Subsequent Event [Line Items]
Proceeds from sale of common stock	$ 125,000

SCHEDULE OF ANTIDILUTIVE SECURI

SCHEDULE OF ANTIDILUTIVE SECURITIES OF EARNINGS PER SHARE (Details) - shares	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	23,467,283	17,431,756
Common Stock to be Issued [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	17,507,283	651,281
Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities		10,440,000
Share-based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	1,900,000	2,193,750
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	4,060,000	4,146,725

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING PRINCIPLES (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Cash Equivalents, at Carrying Value	$ 0		$ 0		$ 0
Equity method investment, ownership percentage	20.00%		20.00%
Proceeds from Sale of Equity Method Investments			$ 100,000
Research and development expenses			$ 7,243	$ 94,048
Antidilutive securities			23,467,283	17,431,756
Athens Encapsulation Inc [Member]
Proceeds from Sale of Equity Method Investments			$ 100,000

SCHEDULE OF INTANGIBLE ASSETS (

SCHEDULE OF INTANGIBLE ASSETS (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Licensed patents	$ 492,514	$ 492,514
Accumulated amortization	(113,132)	(89,665)
Balance	$ 379,382	$ 402,849

SCHEDULE OF FUTURE AMORTIZATION

SCHEDULE OF FUTURE AMORTIZATION OF INTANGIBLE ASSETS (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
2021 (months remaining)	$ 7,823
2022	31,299
2023	31,299
2024	31,299
2025	31,299
Thereafter	246,363
Balance	$ 379,382	$ 402,849

INTANGIBLE ASSETS (Details Narr

INTANGIBLE ASSETS (Details Narrative) - License Agreement [Member] - Massachusetts General Hospital [Member] - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of outstanding common shares			20.00%
Intangible assets remaining amortized period			16 years
Amortization of Intangible Assets	$ 7,823	$ 7,862	$ 23,467	$ 23,587

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	Jun. 21, 2019	Dec. 22, 2017	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Related Party Transaction [Line Items]
Accounts payable			$ 134,180		$ 134,180		$ 236,180
Research and development expenses					7,243	$ 94,048
Professional fees			79,465	15,925	130,828	302,259
Accrued salaries			115,312		115,312		115,312
Proceeds from sale of equity method investment					100,000
Federico Pier [Member]
Related Party Transaction [Line Items]
Accounts payable			75,000		75,000		67,500
Professional fees			22,500	22,500	67,500	67,500
Jeff Wright [Member]
Related Party Transaction [Line Items]
Accounts payable			50,180		50,180		45,000
Professional fees			15,000	15,000	45,000	45,000
Former CEO [Member]
Related Party Transaction [Line Items]
Incurred salaries			35,554	35,554	172,354	172,354
CEO [Member]
Related Party Transaction [Line Items]
Accrued salaries			115,312		115,312		115,312
Massachusetts General Hospital [Member]
Related Party Transaction [Line Items]
Accounts payable			0		0		101,180
Research and development expenses			0	0	7,243	94,048
Consulting Agreement [Member]
Related Party Transaction [Line Items]
Related party expenses				$ 0		$ 18,000
Accounts payable			$ 9,000		9,000		$ 9,000
License Agreement [Member]
Related Party Transaction [Line Items]
Fundraising amount		$ 2,000,000
Fundraising description		The Company has raised $1 million and is currently in the process of raising the second $1 million. The Company and MGH are currently negotiating extending this milestone
Royalty rate on sales		1.00%
Related parties, description		The License Agreement additionally requires VI to pay to MGH a $1.0 million “success payment” within 60 days after the first achievement of total net sales of Product or Process equal to or to exceed $100,000,000 in any calendar year and $4,000,000 within sixty (60) days after the first achievement of total net sales of Product or Process equal or exceed $250,000,000 in any calendar year. The Company is also required to reimburse MGH’s expenses in connection with the preparation, filing, prosecution and maintenance of all Patent Rights
License Agreement [Member] | Massachusetts General Hospital [Member]
Related Party Transaction [Line Items]
Payment to related party					$ 1,000,000
Initial Term [Member] | Consultant [Member] | Consulting Agreement [Member]
Related Party Transaction [Line Items]
Payment to related party	$ 3,000
Fees increasing	6,000
Fundraising amount	$ 5,000,000

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)	Jun. 21, 2019	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Professional fees		$ 79,465	$ 15,925	$ 130,828	$ 302,259
Accounts payable		496,555		$ 496,555		$ 501,732
License Agreement [Member] | Massachusetts General Hospital [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage for royalty				1.00%
License agreement, description				The License Agreement additionally requires VI to pay to MGH a $1.0 million “success payment” within 60 days after the first achievement of total net sales of Product or Process equal or exceeding $100,000,000 in any calendar year and $4,000,000 within sixty (60) days after the first achievement of total net sales of Product or Process equal to or exceeding $250,000,000
Payment for related party				$ 1,000,000
Consulting Agreement [Member] | C And H Capital, Inc [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payment for related party	$ 3,500
Agreement term	1 year
Professional fees			$ 0		$ 21,000
Number of stock option granted	50,000
Exercise price	$ 0.25
Accounts payable		$ 14,000		$ 14,000		$ 14,000

SCHEDULE OF STOCK OPTIONS ACTIV

SCHEDULE OF STOCK OPTIONS ACTIVITY (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Equity [Abstract]
Number of Options, Outstanding, balance	1,900,000	1,900,000
Weighted-Average Exercise Price per Share, Outstanding, Ending	$ 0.66	$ 0.66
Weighted-Average Remaining Life (Years), Outstanding, Ending	6 years 29 days	6 years 9 months 29 days
Number of Options, Exercisable	1,875,000
Weighted-Average Exercise Price per Share, Exercisable	$ 0.67
Weighted-Average Remaining Life (Years), Exercisable	6 years 21 days

SCHEDULE OF WARRANTS ACTIVITY (

SCHEDULE OF WARRANTS ACTIVITY (Details) - Warrant [Member]	9 Months Ended
	Sep. 30, 2021$ / sharesshares
Class of Warrant or Right [Line Items]
Number of Warrants, Outstanding and exercisable, Beginning balance | shares	4,146,725
Weighted-Average Exercise Price per Share, Outstanding and exercisable, Beginning balance | $ / shares	$ 0.53
Weighted-Average Remaining Life (Years), Outstanding and exercisable, Ending	1 year 6 months
Number of Warrants, Expired | shares	86,725
Weighted-Average Exercise Price per Share, Expired | $ / shares	$ 1.85
Number of Warrants, Outstanding and exercisable, Ending balance | shares	4,060,000
Weighted-Average Exercise Price per Share, Outstanding and exercisable, Ending balance | $ / shares	$ 0.50
Weighted-Average Remaining Life (Years), Outstanding and exercisable, Ending	9 months 3 days

STOCKHOLDERS_ EQUITY (DEFICIT_2

STOCKHOLDERS’ EQUITY (DEFICIT) (Details Narrative) - USD ($)	Feb. 12, 2021	Dec. 19, 2017	Sep. 30, 2021	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Sep. 13, 2017
Class of Stock [Line Items]
Preferred stock, shares authorized			20,000,000	20,000,000		20,000,000		20,000,000	20,000,000
Preferred stock par value			$ 0.001	$ 0.001		$ 0.001		$ 0.001	$ 0.001
Number of common stock issued			1,540,000
Common stock, shares authorized			300,000,000	300,000,000		300,000,000		300,000,000	300,000,000
Common stock par value			$ 0.001	$ 0.001		$ 0.001		$ 0.001	$ 0.001
Common stock, shares outstanding			17,561,550	17,561,550		17,561,550		17,483,283
Proceeds from issuance of common stock			$ 385,000			$ 385,000
Number of common stock to be issued						17,507,283		651,281
Stock Subscription Agreements [Member]
Class of Stock [Line Items]
Number of common stock to be issued						1,540,000
Stock Issuance and Release Agreement [Member]
Class of Stock [Line Items]
Number of common stock to be issued						597,281	621,281
Shares issued price per share			$ 1.85	$ 1.85		$ 1.85
Stock Issuance and Release Agreement [Member] | Two Shareholders [Member]
Class of Stock [Line Items]
Number of common stock to be issued						30,000	30,000
Private Placement [Member]
Class of Stock [Line Items]
Sale of stock, number of shares issued in transaction						1,540,000
Sale of stock, price per share			$ 0.25	$ 0.25		$ 0.25
Proceeds from issuance of common stock						$ 385,000
Stock Options [Member]
Class of Stock [Line Items]
Share-based Payment Arrangement, Expense				$ 1,081	$ 2,883	$ 3,244	$ 13,699
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross						25,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount			$ 3,245	$ 3,245		$ 3,245
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition						6 months
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized		3,000,000	3,000,000	3,000,000		3,000,000		3,000,000
Preferred stock par value		$ 0.001	$ 0.001	$ 0.001		$ 0.001		$ 0.001
Preferred stock voting rights		Each holder of shares of Series A Preferred Stock shall be entitled to the number of votes equal to the number of votes held by the number of shares of common stock into which such share of Series A Preferred Stock could be converted, and except as otherwise required by applicable law, shall have the voting rights and power equal to the voting rights and powers of the common stock
Preferred stock conversion price per share		$ 1.67
Preferred stock conversion, description		Each share of Series A Preferred Stock is convertible into shares of common stock at a conversion Rate of 2:1 (the “Series A Conversion Rate”)
Number of common stock issued	6,000,000
Preferred stock, shares issued			0	0		0		3,000,000
Preferred stock, shares outstanding			0	0		0		3,000,000
Number of common stock to be issued	6,000,000					6,000,000
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized		4,440,000	4,440,000	4,440,000		4,440,000		4,440,000
Preferred stock par value		$ 0.001	$ 0.001	$ 0.001		$ 0.001		$ 0.001
Preferred stock voting rights		Each holder of shares of Series B Preferred Stock shall be entitled to the number of votes equal to the number of votes held by the number of shares of common stock into which such share of Series B Preferred Stock could be converted, and except as otherwise required by applicable law, shall have the voting rights and power equal to the voting rights and powers of the common stock
Preferred stock conversion price per share		$ 0.83
Preferred stock conversion, description		The holder of Series B Preferred Stock may elect at any time to convert such sharers into common stock of the Company. Each share of Series B Preferred Stock is convertible into shares of common stock at a conversion rate of 1:1 (the “Series B Conversion Rate”)
Number of common stock issued	4,440,000
Preferred stock, shares issued			0	0		0		4,440,000
Preferred stock, shares outstanding			0	0		0		4,440,000
Number of common stock to be issued	4,440,000					4,440,000

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - USD ($)	Oct. 01, 2021	Sep. 30, 2021	Jun. 30, 2021	Sep. 30, 2021	Sep. 30, 2020
Subsequent Event [Line Items]
Proceeds from sale of common stock		$ 385,000		$ 385,000
Subsequent Event [Member]
Subsequent Event [Line Items]
Proceeds from sale of common stock	$ 125,000
Accredited Investors [Member] | Security Purchase Agreements [Member]
Subsequent Event [Line Items]
Sale of stock price per share			$ 0.25
Accredited Investors [Member] | Security Purchase Agreements [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Proceeds from sale of common stock	$ 125,000
Maximum [Member] | Accredited Investors [Member] | Security Purchase Agreements [Member]
Subsequent Event [Line Items]
Proceeds from sale of common stock			$ 1,000,000